Northern Trust’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-45,135
| Closed | -$28K | – | 4337 |
|
|
2018
Q4 | $28K | Sell |
45,135
-716
| -2% | -$743 | ﹤0.01% | 4123 |
|
|
2018
Q3 | $60K | Sell |
45,851
-6
| -0% | -$9 | ﹤0.01% | 4115 |
|
|
2018
Q2 | $62K | Sell |
45,857
-253,973
| -85% | -$389K | ﹤0.01% | 4095 |
|
|
2018
Q1 | $435K | Buy |
299,830
+5,825
| +2% | +$12.2K | ﹤0.01% | 3610 |
|
|
2017
Q4 | $661K | Buy |
294,005
+1,854
| +0.6% | +$4.69K | ﹤0.01% | 3499 |
|
|
2017
Q3 | $993K | Sell |
292,151
-5,903
| -2% | -$19.9K | ﹤0.01% | 3437 |
|
|
2017
Q2 | $1.06M | Buy |
298,054
+58,134
| +24% | +$192K | ﹤0.01% | 3426 |
|
|
2017
Q1 | $816K | Sell |
239,920
-4,255
| -2% | -$16.5K | ﹤0.01% | 3414 |
|
|
2016
Q4 | $1.12M | Buy |
244,175
+914
| +0.4% | +$3.77K | ﹤0.01% | 3315 |
|
|
2016
Q3 | $1.03M | Buy |
243,261
+104,086
| +75% | +$337K | ﹤0.01% | 3338 |
|
|
2016
Q2 | $334K | Buy |
139,175
+24,844
| +22% | +$89.8K | ﹤0.01% | 3597 |
|
|
2016
Q1 | $537K | Sell |
114,331
-1,682
| -1% | -$6.51K | ﹤0.01% | 3448 |
|
|
2015
Q4 | $456K | Sell |
116,013
-496
| -0.4% | -$2.29K | ﹤0.01% | 3537 |
|
|
2015
Q3 | $451K | Buy |
116,509
+101,011
| +652% | +$464K | ﹤0.01% | 3523 |
|
|
2015
Q2 | $72K | Buy |
+15,498
| New | +$149K | ﹤0.01% | 4005 |
|
Northern Trust's AST Position: Q1 2019 in Review
Northern Trust sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 45,135 shares — an estimated $28K sold.
Northern Trust first reported a position in AST in Q2 2015 and held it in 15 quarters. The position peaked at $1.12M in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Northern Trust reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Northern Trust sold 45,135 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $28K.
- Northern Trust first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 15 quarters.
- Northern Trust's Asterias Biotherapeutics Inc. Series A position peaked at $1.12M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Northern Trust's 13F filing for Q1 2019, filed 13 May 2019.